Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

Annals of Surgical Oncology

Volumn 24, Issue 8, 2017, Pages 2161-2167

  Clifton, G Travis ^a   Litton, Jennifer K ^a   Arrington, Karen ^b   Ponniah, Sathibalan ^c   Ibrahim, Nuhad K ^a   Gall, Victor ^a   Alatrash, Gheath ^a   Peoples, George E ^b,d   Mittendorf, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cancer Vaccine Development Program   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PEPTIDE VACCINE; TRASTUZUMAB; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE FRAGMENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INJECTION SITE PRURITUS; INOCULATION; PHASE 1 CLINICAL TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PROGNOSIS; VACCINATION;

ADULT; BREAST NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; RECEPTOR, ERBB-2; TRASTUZUMAB; VACCINATION;

EID: 85015619717     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-017-5844-0     Document Type: Article

References (29)

1. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
2. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62.
3. Beano A, Signorino E, Evangelista A, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:25.
4. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122(3):1066–1075.
5. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002;195(1):125–133.
6. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 2002;110(1):71–79.
7. Knutson KL, Clynes R, Shreeder B, et al. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. Cancer Res. 2016;76(13):3702–3710.
8. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13(17):5133–5143.
9. Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010;116(2):292–301.
10. Mittendorf EA, Ardavanis A, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7(40):66192–66201.
11. Jordan TJ, Sunderam G, Thomas L, Reichman LB. Tuberculin reaction size measurement by the pen method compared to traditional palpation. Chest. 1987;92(2):234–236.
12. Bahl S, Roses RE, Sharma A, et al. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines. Am J Surg. 2009;198(4):488–494.
13. Holmes JP, Benavides LC, Gates JD, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008;26(20):3426–3433.
14. Mittendorf EA, Ardavanis A, Symanowski J, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016;27(7):1241–1248.
15. Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735–42.
16. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Caner Res. 2008;14(3):797–803.
17. Chen G, Gupta R, Petrik S, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2(10):949–961.
18. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27(28):4685–4692.
19. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009;15(8):2895–2904.
20. Benavides LC, Sears AK, Gates JD, et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines. 2011;10(2):201–210.
21. Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg. 2010;210(2):140–147.
22. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A. 1995;92(2):432–436.
23. Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery. 2006;139(3):407–418.
24. Mittendorf EA, Storrer CE, Foley RJ, et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer. 2006;106(11):2309–2317.
25. Kuhns JJ, Batalia MA, Yan S, Collins EJ. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem. 1999;274(51):36422–36427.
26. Cancer Insight, LLC. Phase II trial of combination immunotherapy with NeuVax and Trastuzumab in high-risk HER2+ breast cancer patients. Available at: https://clinicaltrials.gov/ct2/show/NCT02297698. Accessed 15 Feb 2017.
27. George E. Peoples. Combination immunotherapy with Herceptin and the HER2 vaccine NeuVax. Available at: https://clinicaltrials.gov/ct2/show/NCT01570036. Accessed 15 Feb 2017.
28. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–3752.
29. Mittendorf EA, Storrer CE, Shriver CS, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006;13(8):1085–1098.